HK94096A - The use of certain calcium-citrate-malate for the manufacture of a medicament for the treatment of osteoporosis - Google Patents

The use of certain calcium-citrate-malate for the manufacture of a medicament for the treatment of osteoporosis Download PDF

Info

Publication number
HK94096A
HK94096A HK94096A HK94096A HK94096A HK 94096 A HK94096 A HK 94096A HK 94096 A HK94096 A HK 94096A HK 94096 A HK94096 A HK 94096A HK 94096 A HK94096 A HK 94096A
Authority
HK
Hong Kong
Prior art keywords
calcium
malate
calcium citrate
citrate
osteoporosis
Prior art date
Application number
HK94096A
Other languages
English (en)
French (fr)
Inventor
Ann Kochanowski Barbara
Original Assignee
Norwich Eaton Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Norwich Eaton Pharmaceuticals, Inc. filed Critical Norwich Eaton Pharmaceuticals, Inc.
Publication of HK94096A publication Critical patent/HK94096A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A23L33/165—Complexes or chelates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Non-Alcoholic Beverages (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Claims (8)

  1. Verwendung von Calciumcitratmalat zur Herstellung eines Arzneimittels für die Behandlung von Osteoporose, wobei dieses Calciumcitratmalat ein Molverhältnis von Citrat:Malat von 1:0,5 bis 1:4,5 aufweist.
  2. Verwendung nach Anspruch 1, wobei das Calciumcitratmalat ein Molverhältnis von Citrat:Malat von 1:0,75 bis 1:3 aufweist.
  3. Verwendung nach Anspruch 1, wobei das Calciumcitratmalat ein Molverhältnis von Calcium:Gesamtmolen Citrat plus Malat von 1:0,7 bis 1:0,9 aufweist.
  4. Verwendung nach Anspruch 3, wobei die Calcium-Äquivalente in dem genannten Calciumcitratmalat gleich der Gesamtanzahl von Citrat-Äquivalenten plus Malat-Äquivalenten in dem genannten Calciumcitratmalat sind.
  5. Verwendung nach einem der vorstehenden Ansprüche, wobei das das Calciumcitratmalat enthaltende Arzneimittel in einer festen Dosierungsform vorliegt.
  6. Verwendung nach einem der vorstehenden Ansprüche, wobei das das Calciumcitratmalat enthaltende Arzneimittel in einer flüssigen Dosierungsform vorliegt.
  7. Verwendung nach Anspruch 6, wobei die flüssige Dosierungsform ein safthältiges Getränk ist.
  8. Verwendung nach einem der vorstehenden Ansprüche, wobei das Arzneimittel in der Form einer Einheitsdosis vorliegt, welche 100 mg bis 1.000 mg an Calciumcitratmalat enthält.
HK94096A 1987-08-28 1996-05-30 The use of certain calcium-citrate-malate for the manufacture of a medicament for the treatment of osteoporosis HK94096A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9100687A 1987-08-28 1987-08-28

Publications (1)

Publication Number Publication Date
HK94096A true HK94096A (en) 1996-06-07

Family

ID=22225323

Family Applications (1)

Application Number Title Priority Date Filing Date
HK94096A HK94096A (en) 1987-08-28 1996-05-30 The use of certain calcium-citrate-malate for the manufacture of a medicament for the treatment of osteoporosis

Country Status (9)

Country Link
EP (1) EP0304986B1 (de)
JP (1) JP2738541B2 (de)
KR (1) KR970009582B1 (de)
AT (1) ATE88633T1 (de)
CA (1) CA1329774C (de)
DE (1) DE3880587T2 (de)
HK (1) HK94096A (de)
IE (1) IE61451B1 (de)
PH (1) PH25585A (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5108761A (en) * 1990-10-01 1992-04-28 The Procter & Gamble Company Method of preventing tooth enamel erosion utilizing an acidic beverage containing calcium
JPH06502310A (ja) * 1990-10-31 1994-03-17 ザ、プロクター、エンド、ギャンブル、カンパニー カルシウム強化ソース
EP0622992B1 (de) * 1991-12-26 1998-10-14 The Procter & Gamble Company Lagerstabile getränkskonzentrate mit kalziumzusatz
US5389387A (en) * 1991-12-26 1995-02-14 The Procter & Gamble Company Storage stable calcium-supplemented beverage concentrates
AU4597293A (en) * 1992-06-30 1994-01-24 Procter & Gamble Company, The Effervescent calcium supplements
ES2089858T3 (es) * 1992-10-21 1996-10-01 Procter & Gamble Concentrados de premezcla para bebidas suplementados con calcio y estables en almacenamiento.
WO1994008471A1 (en) * 1992-10-21 1994-04-28 The Procter & Gamble Company Sweetener containing a concentrated bioavailable calcium source
CA2146633C (en) * 1992-10-21 1998-09-01 Mark Benson Andon Concentrated bioavailable calcium source
IT1256300B (it) * 1992-11-05 1995-11-29 Dompe Farmaceutici Spa Uso di acidi aril-, eteroaril- e alchiltartronici come agenti terapeutici
US6811800B2 (en) 1998-09-29 2004-11-02 The Procter & Gamble Co. Calcium fortified beverages
CA2343024A1 (en) * 1998-09-29 2000-04-06 The Procter & Gamble Company Low acid beverages supplemented with nutritional calcium sources
CN101505730B (zh) * 2006-08-17 2013-02-13 宝洁公司 包含柠檬酸苹果酸钙的组合物以及它们的制备方法
TR200908237A2 (tr) 2009-11-02 2011-05-23 Bi̇lgi̇ç Mahmut Kalsiyum ve D vitamini içeren farmasötik bileşimler.
WO2012125524A1 (en) * 2011-03-16 2012-09-20 The Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Medical Center Compositions and methods for the treatment of musculoskeletal related diseases and disorders using metal ion-citrate analog complexes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5697248A (en) * 1979-12-28 1981-08-05 Tanaka Shiro Conjugated compound of calcium citrate and calcium malate and its preparation
FR2601249A1 (fr) * 1986-07-09 1988-01-15 Sandoz Lab Nouvelles compositions pharmaceutiques a base de sels de calcium.
US4786510A (en) * 1987-07-02 1988-11-22 The Procter & Gamble Company Calcium-iron mineral supplements

Also Published As

Publication number Publication date
EP0304986A2 (de) 1989-03-01
EP0304986A3 (en) 1990-03-07
PH25585A (en) 1991-08-08
DE3880587T2 (de) 1993-09-23
ATE88633T1 (de) 1993-05-15
KR890003390A (ko) 1989-04-14
IE61451B1 (en) 1994-11-02
IE882609L (en) 1989-02-28
JPH01151515A (ja) 1989-06-14
CA1329774C (en) 1994-05-24
DE3880587D1 (de) 1993-06-03
JP2738541B2 (ja) 1998-04-08
KR970009582B1 (en) 1997-06-14
EP0304986B1 (de) 1993-04-28

Similar Documents

Publication Publication Date Title
US5128374A (en) Use of calcium citrate malate for the treatment of osteoporosis and related disorders
JP3708115B2 (ja) 混合カルシウム及びビタミンｄ補給品
EP0542912B1 (de) Zusätze aus calcium und spurenelementen
AU666654B2 (en) Calcium, trace mineral, vitamin D and drug therapy combinations
US5232709A (en) Calcium and trace mineral supplements comprising estrogen
EP0304987B1 (de) Kalziumzusätze
HK1006149B (en) Calcium and trace mineral supplements
EP0304986B1 (de) Verwendung von bestimmten Calcium-Citrate-Malaten zur Herstellung einer pharmazeutischen Zubereitung für die Behandlung von Osteoporose.
US5314919A (en) Calcium supplements
GB2210243A (en) A magnesium additive for nutrients, feed, and medicaments
US5905093A (en) Fish scale extract as a calcium supplement
WO1999040941A1 (en) A fish scale extract as a calcium supplement

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20080814